Monte Rosa Therapeutics (GLUE) filed a registration statement Thursday for the potential sale of up to $400 million of various securities.
The prospectus covers the sale of the company's debt securities, common stock, preferred stock, units and warrants from time to time.
Monte Rosa said it intends to use the net proceeds from the sale of any securities for general corporate purposes, which may include research and development and clinical development costs to support the advancement of its product candidates and the expansion of its research and development programs.
Price: 7.20, Change: +0.50, Percent Change: +7.46
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。